rockwell-logo2.jpg
Rockwell Medical Submits Investigational New Drug Application with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion
11. November 2021 08:30 ET | Rockwell Medical, Inc.
WIXOM, Mich., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
rockwell-logo2.jpg
Rockwell Medical, Inc. to Report Third Quarter 2021 Financial and Operating Results on November 15, 2021
08. November 2021 07:00 ET | Rockwell Medical, Inc.
WIXOM, Mich., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
rockwell-logo2.jpg
Rockwell Medical Presents Triferic® Real World Evidence Update at ASN Kidney Week 2021
04. November 2021 16:01 ET | Rockwell Medical, Inc.
-Results from pilot observational analysis demonstrate maintenance of hemoglobin and reduction of total IV iron requirement in adult patients on Triferic receiving chronic hemodialysis-  -Findings...
rockwell-logo2.jpg
Rockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09. September 2021 09:52 ET | Rockwell Medical, Inc.
WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
rockwell-logo2.jpg
Rockwell Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
19. August 2021 16:00 ET | Rockwell Medical, Inc.
WIXOM, Mich., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of...
rockwell-logo2.jpg
Rockwell Medical, Inc. Provides Second Quarter 2021 Financial and Operational Update
16. August 2021 16:09 ET | Rockwell Medical, Inc.
-Entered into exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic® in Turkey- -Extended multi-year distribution agreement with Nipro Medical for dialysis...
Rockwell Medical, Inc. logo
Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021
29. Juli 2021 07:00 ET | Rockwell Medical, Inc.
WIXOM, Mich., July 29, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
Rockwell Medical, Inc. logo
Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion
28. Juni 2021 07:00 ET | Rockwell Medical, Inc.
WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
Rockwell Medical, Inc. logo
Rockwell Medical Announces Extension of Multi-Year Distribution Agreement with Nipro Medical Corporation for Dialysis Concentrates
11. Juni 2021 12:20 ET | Rockwell Medical, Inc.
WIXOM, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
Rockwell Medical, Inc. logo
Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic® in Turkey
08. Juni 2021 07:00 ET | Rockwell Medical, Inc.
WIXOM, Mich. and ANKARA, Turkey, June 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and...